xAnts

xAnts

en-AU

Halozyme plans finance $2.1 takeover of Evotech in cash: report

2024-11-17

finance

Halozyme plans finance $2.1 takeover of Evotech in cash: report

Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany's Evotec (EVO) in cash, Bloomberg reported Sunday, quoting Chief Executive Helen Torley. "We feel confident in being able to fund this as a fully ...Read more

Recommendations